Futures slip, bank earnings ahead, Powell to speak - what’s moving markets
Gilde Healthcare Holding B.V. and Cooperatieve Gilde Healthcare IV U.A., both ten percent owners of LAVA Therapeutics NV (NASDAQ:LVTX), reported selling a combined total of 126,992 common shares between October 8 and October 10, 2025. The sales, executed in multiple transactions, amounted to $197,898 with prices ranging from $1.55 to $1.57 per share. The transactions come as LVTX, currently valued at $40.88 million, has seen its stock surge 63% year-to-date despite rapidly depleting cash reserves.
On October 8, 28,954 shares were sold at a weighted average price of $1.57, with individual sales prices ranging from $1.56 to $1.62. The following day, October 9, 48,169 shares were sold at an average price of $1.56, in a range of $1.54 to $1.59. On October 10, the entities sold 49,869 shares at an average price of $1.55, with prices varying between $1.53 and $1.58.
Following these transactions, Cooperatieve Gilde Healthcare IV U.A. directly holds 5,294,178 LAVA Therapeutics NV shares.
In other recent news, XOMA Royalty Corporation has announced the extension of its tender offer deadline to acquire all outstanding shares of LAVA Therapeutics until October 17, 2025. This acquisition involves a cash payment per share, plus a non-transferable contingent value right representing 75% of net proceeds from LAVA’s partnered and unpartnered assets. Additionally, XOMA has entered into an agreement to acquire HilleVax, Inc., involving cash payments and contingent value rights tied to potential future proceeds. Jefferies has downgraded LAVA Therapeutics from Buy to Hold, adjusting its price target from $3.00 to $1.50 following the acquisition news. The acquisition by XOMA will see LAVA shareholders receive between $1.16 and $1.24 per share in cash. These developments are part of XOMA’s strategic moves to expand its portfolio through acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.